Cordyceps is a traditional vitality fungus, mainly cultivated Cordyceps militaris or related culture products. Strongest clinical signals are add-on kidney blood-marker gains and some cancer-care support, still limited by trial bias. Exercise effects are conflicted and product-dependent. Food-like doses are generally well tolerated; key cautions are immune effects, blood sugar, surgery bleeding risk, and product quality. (Full Review)

Protocol

Dose

1,000–3,000 mg/day

Common studied oral range (Cs-4 or powder/extract); traditional/renal literature sometimes 3–6 g/day

Form

C. militaris fruiting body or Cs-4 mycelium

Prefer third-party tested identity; avoid unverified wild “sinensis”

Timing

Morning or pre-training

With meals if GI-sensitive; often split 2×/day

Time to effect

Renal markers

Weeks to months

Clinical biomarker shifts in adjunct settings

Exercise tolerance

1–12 weeks

Threshold changes in positive trials

Subjective energy

Days to few weeks

If any; placebo-sensitive

Benefits

Medium: Renal biomarkers in chronic kidney disease (adjunct); Chemotherapy support markers in lung cancer (adjunct)

Low: Aerobic exercise tolerance; Inflammatory and nutritional markers in hemodialysis; Post-exercise muscle recovery signals; Respiratory function in stable chronic obstructive pulmonary disease (adjunct)

Speculative: Immune resilience in healthy adults; Sexual function and libido; Healthy-aging vitality and fatigue (non-renal, non-athletic)

Contraindications

Solid-organ transplant recipients

Active autoimmune disease with unstable control

Pregnancy and breastfeeding (insufficient safety data)

Children

Known mushroom allergy

Planned major surgery within two weeks

Key Interactions

Immunosuppressants (e.g., cyclosporine, tacrolimus, mycophenolate, corticosteroids, azathioprine)

Antidiabetic drugs (insulin, metformin, sulfonylureas such as glipizide, SGLT2 inhibitors such as empagliflozin)

Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)

Other immunomodulatory supplements (e.g., echinacea, high-dose medicinal mushroom stacks, astragalus)

Risk & Side Effects

Medium: Immune activation in autoimmune disease or transplant settings

Low: Gastrointestinal upset; Hypoglycemia risk with concurrent glucose-lowering therapy; Bleeding tendency / perioperative caution; Contaminants and misidentified products

Speculative: Mycotoxin or bioactive safety of novel isolates

Monitoring

Marker	Target	Why
Fasting glucose	≈70–90 mg/dL (functional aim)	Detect additive glucose lowering
HbA1c	≈4.8–5.2% functional aim	Medium-term glycemic exposure
eGFR / serum creatinine	Stable vs personal baseline	Track kidney signal if CKD risk or nephroactive drugs
hs-CRP	<1.0 mg/L preferred	Inflammatory baseline and change
CBC (complete blood count)	Within lab reference	Safety if immunosuppressants or bleeding concern
AST/ALT	Within lab reference	General hepatic safety with multi-herb stacks

Cadence: Baseline before start; 4–8 weeks after stable dose; every 6–12 months if continued long-term, or sooner if symptoms or drug changes. Diabetics: home glucose more frequently for the first 2–4 weeks.

Qualitative Assessment

Subjective energy and afternoon fatigue scores (1–10 log for 2–4 weeks pre/post)
Training metrics: pace/power at a fixed heart rate, time-to-exhaustion on a standard session
GI tolerance (nausea, stool changes)
Infection frequency or autoimmune symptom flares (stop and reassess if flares appear)
Sleep quality (to catch individual overstimulation)

Cordyceps for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment